Attractive Opportunities in Glioblastoma Multiforme Treatment Market by End-user and Geography - Forecast and Analysis 2022-2026

Attractive Opportunities in Glioblastoma Multiforme Treatment Market by End-user and Geography - Forecast and Analysis 2022-2026

TownNews.com Content Exchange

NEW YORK, Nov. 25, 2021 /PRNewswire/ -- Technavio's latest offering, the Glioblastoma Multiforme Treatment Market report provides a detailed analysis of the competitive scenario and the market growth across various regions. The glioblastoma multiforme treatment market is expected to increase by USD 1.41 billion from 2021 to 2026 at a CAGR of 8.48%. 37% of the market's growth will originate from North America. The US and Canada are the key markets for glioblastoma multiforme treatment in the region. The favorable government initiatives will facilitate the glioblastoma multiforme treatment market growth in North America.

For more insights on the Glioblastoma Multiforme Treatment Market - Download a free sample now!

Market Dynamics

Factors such as the increasing incidence of glioblastoma multiforme and the increasing geriatric population will drive the growth of the Glioblastoma Multiforme Treatment Market. However, adverse effects associated with treatments might hamper the market growth.

Company Profiles

The glioblastoma multiforme treatment market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. The glioblastoma multiforme treatment market report provides complete insights on key vendors including Amgen Inc., Amneal Pharmaceuticals Inc., Angiochem Inc., Arbor Pharmaceuticals LLC, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Pfizer Inc., Sumitomo Dainippon Pharma Co. Ltd., and Sun Pharmaceutical Industries Ltd.

Few Companies with Key Offerings

  • Amgen Inc.- The company offers an injection solution namely AMGEVITA for glioblastoma multiforme treatment.
  • Amneal Pharmaceuticals Inc. - The company offers injection solutions namely Acyclovir for glioblastoma multiforme treatment.
  • Angiochem Inc. - The company offers Antibody-drug conjugates (ADCs) for glioblastoma multiforme treatment.

Competitive Analysis

The report includes the competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and market performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Market Segmentation

  • By End-user, the market is classified into Hospitals, Clinics, and Ambulatory Surgical Centers. The glioblastoma multiforme treatment market share growth by the hospital segment has been significant.
  • By Geography, the market is classified as North America, Europe, Asia, and ROW. North America will have the largest share of the market.

Related Reports-

Liposomal Products Market  -The liposomal products market share should rise by USD 2.21 billion from 2021 to 2026 at a CAGR of 7.81%. Download a free sample now!

GERD Market -The GERD market share should rise by USD 793.85 million between 2021 and 2025 at a CAGR of 3.01%. Download a free sample now!

Glioblastoma Multiforme Treatment Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 8.48%

Market growth 2022-2026

USD 1.41 billion

Market structure

Fragmented

YoY growth (%)

6.88

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 37%

Key consumer countries

US, Germany, Canada, China, UK, and Japan

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Amgen Inc., Amneal Pharmaceuticals Inc.,  Angiochem Inc., Arbor Pharmaceuticals LLC, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Pfizer Inc., Sumitomo Dainippon Pharma Co. Ltd., and Sun Pharmaceutical Industries Ltd.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.comWebsite: www.technavio.com/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/glioblastoma-multiforme-treatment-market-to-grow-by-usd-1-41-billion--evolving-opportunities-with-amgen-inc--amneal-pharmaceuticals-inc--17000-technavio-reports-301431542.html

SOURCE Technavio

This article originally ran on curated.tncontentexchange.com.

TownNews.com Content Exchange

Trending Food Videos